NJ-FORK-&-GOOD
14.3.2023 13:01:48 CET | Business Wire | Press release
After four years of being in stealth, Fork and Good is emerging with the launch of its pilot facility in Jersey City, where it will initially focus on producing cultivated pork with the goal of expanding to other types of meat in the future. The company has raised $22 million to date from investors, led by True Ventures with participation from Leaps by Bayer, Collaborative Fund, Firstminute, Green Monday, Starlight, and others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005208/en/
Steamed dumplings made with delicious Fork & Good cultivated pork (Photo: Business Wire)
Fork and Good is working to offset an existential crisis in conventional pork farming caused by a rise in viral diseases and antibiotic resistance, shrinking water and land resources, as well as concerns about its environmental impact. Combined, these factors have weakened the pork supply chain and contributed to price volatility that threatens to put meat out of reach for many consumers in the near future.
“To sustainably feed 10 billion people by 2050, we need to prioritize the development of alternative protein sources that are both nutritious and affordable at scale, using a fraction of the resources required today. We're excited to see Fork and Good making progress toward this vision,” said Juergen Eckhardt, Head of Leaps by Bayer.
Fork and Good’s initial focus on ground pork aims to help solve supply chain instability in the massive $820 billion global pork market. Its approach is differentiated at the start, as it cultivates muscle cells instead of stem cells, which allows for simpler, cheaper production. Simpler because they only grow meat cells. Cheaper because they don’t need to modify stem cells or other types of cells. Instead of growing cells using scaffolds, the company uses a patented bioprocess and unique bioreactors that increase yield and allow for higher density of production.
“Achieving high yields at an affordable price point is incredibly complex, and Fork and Good is uniquely equipped for the task,” said Adam D’Augelli, True Ventures. “Its Jersey City facility can produce six to ten times more pork per square foot than would be possible using traditional farming methods, with far less water and minimal impact on the surrounding ecosystem."
“Opening our pilot facility brings us one step closer to fulfilling our mission of producing cultivated pork that is both delicious and accessible,” added Niya Gupta, Fork and Good co-founder and CEO. “Given the hype in the space, we didn’t want to go public until we had something real.”
Niya is no stranger to the two-pronged challenge of yield and affordability; prior to Fork and Good, she co-founded ComCrop, an urban farming startup in Singapore that leverages hydroponics to grow large volumes of produce in a small space.
“From my experience in hydroponics, it became clear that low yield was the reason cultivated meat was so expensive,” said Niya. “We measure yield by feed conversion in livestock, and it was too low in cultivated meat. Our feed conversion is already close to that for pigs and we’re on track to be better.”
Niya’s agricultural knowledge is augmented by decades of scientific expertise from co-founder and Chief Scientific Officer Gabor Forgacs. A pioneering biophysicist with a 30+ year academic career, Gabor first introduced the world to cultivated meat on the TEDMED stage in 2011. He is the Scientific Founder of Organovo, a bioprinting company, and Modern Meadow, the first cultivated meat company that today engineers bio-fabricated materials that limit greenhouse gas emissions.
“Making cultivated meat does not require fundamentally new science,” explained Gabor. “Increasing yield at scale requires true innovation. That’s why we’ve focused so much on the process, patenting an approach that is both innovative and economically sound.”
Fork and Good began with a sense of urgency around bringing cultivated meat to market, and is now forging partnerships with food industry leaders to help ensure a future where everyone can access safe, humanely-produced meat that is good for people and the planet.
ABOUT FORK AND GOOD
From its facility in Jersey City, Fork & Good is on a mission to grow the best of meat for everyone, everywhere. The company takes a novel approach to cultivating meat by growing muscle cells directly in proprietary bioreactors for maximum flavor and nutritional value—while drastically reducing the amount of land and water used in conventional livestock production. The team has 150+ years of combined experience that spans food, agriculture, and science, and is committed to helping build the industry in a safe, transparent way. Learn more at: www.forkandgood.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005208/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
